Management and diagnosis of dry eye

Article

The TearLab Osmolarity System is the Gold Standard for diagnosing and managing Dry Eye Disease with a quantitative, objective endpoint.

Dry Eye - Management and diagnosis

The TearLab Osmolarity System is the first objective and quantitative test for diagnosing and managing Dry Eye patients.

  • Provides fast and accurate results in seconds using only 50 nanolitres (nL) of tear film to diagnose Dry Eye Disease
  • Enables discussion with patients around a number, improving compliance
  • Incorporating osmolarity into the standard of care gives the best indication of early stage disease

The TearLab Osmolarity System is intended to measure the osmolarity of tears to aid in the diagnosis of dry eye disease, in conjunction with other methods of clinical evaluation. TearLab is for professional in vitro diagnostic use only.

Hyperosmolarity has been described in the literature as a primary marker of tear film integrity. When the quantity or quality of secreted tears is compromised (known as aqueous deficient or evaporative Dry Eye Disease), increased rates of evaporation lead to a more concentrated tear film (increased osmolarity) that places stress on the corneal epithelium and conjunctiva.

Company name: TearLab Corp
Address: 9980 Huennekens St. Ste. 100 San Diego, California 92121, USA
Telephone: +1 866-877-TEAR
E-mail: sales@tearlab.comWebsite: www.tearlab.com

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.